Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling
Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling
复制标题
DOI：
10.1111/crj.12970
复制
发表时间：
2018-11
期刊：
影响因子：
--
通讯作者：
Yong-hong Pan;Caiyu Lin;Cong-hua Lu;Li Li-Li;Yubo Wang;Hengyi Chen;Yong He
中科院分区：
文献类型：
--
作者：
Yong-hong Pan;Caiyu Lin;Cong-hua Lu;Li Li-Li;Yubo Wang;Hengyi Chen;Yong He
第三代不可逆表皮生长因子受体酪氨酸激酶抑制剂（EGFR - TKI） rociletinib （CO - 1686）对携带T790M耐药突变的EGFR -突变患者疗效显著。然而，可能会出现获得性耐药性。有必要表征获得性电阻机制，并设计克服CO - 1686电阻的方法。
Third‐generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), rociletinib (CO‐1686), is great efficacy against EGFR‐mutated patients bearing the T790M resistance mutation. However, acquired resistance may emerge. There is a need to characterize acquired resistance mechanism(s) and to devise ways to overcome CO‐1686 resistance.